Numinus Wellness Inc (PK) (NUMIF)

If they get relisted, BAM!
GLTA 

Numinus Wellness Provides Update Regarding Listing StatusMarch 24, 2026 5:00 PM
NewsfileVancouver, British Columbia--(Newsfile Corp. - March 24, 2026) - Numinus Wellness Inc. (TSX: NUMI) (OTC Pink: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with an emphasis on safe, evidence-based psychedelic-assisted therapies, is providing an update regarding its listing status on the Toronto Stock Exchange ("TSX").As previously disclosed in the Company's management information circular dated July 29, 2025, and as approved by shareholders at the Company's annual general meeting held on August 28, 2025 (with voting results subsequently disclosed on September 3, 2025), shareholders authorized the Board of Directors, in its discretion, to voluntarily delist the Company's common shares from the TSX if deemed to be in the best interests of the Company.Further to Numinus' news release of March 13, 2026, on March 19, 2026 the Continued Listing Committee of the TSX met and determined to delist the Company's common shares from the TSX, effective April 22, 2026. While this delisting does not result from a request from the Company, it is consistent with the authorization of the shareholders to delist Numinus from the TSX, and aligns with the Company's previously disclosed strategic considerations.As the Company remains subject to a cease trade order (the "CTO"), the delisting from the TSX will not change the current trading status of its securities, which are not presently tradable in Canada. The Company will continue to be a reporting issuer in all applicable Canadian jurisdictions.Looking ahead for Numinus, management is pleased to advise that an application has been filed to list the Company's shares on the Canadian Securities Exchange (the "CSE"). If approved, a listing on the CSE could only take effect after the CTO has been revoked. The listing of the Company's common shares on the CSE is subject to the Company meeting the CSE's listing requirements, which cannot be guaranteed.Management remains focused on:completing the work to have the audit completed for the Company's financial statements for the year ended August 31, 2026;satisfying all regulatory requirements necessary to have the CTO revoked; andadvancing an application to list its common shares on the CSE.Successfully executing these steps remains management's primary strategy to restore trading, enhance shareholder liquidity, and position the Company for its next phase of growth.About NuminusNuminus Wellness Inc. (TSX: NUMI) (OTC Pink: NUMIF) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model - including psychedelic research and training - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society. Learn more at www.numinusnetwork.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.SOURCE Numinus Wellness Inc.Forward-looking statements This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including, without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are "forward-looking statements". Forward-looking statements can be identified by the use of words such as "expects", "does not expect", "is expected", "believes", "intends", "anticipates", "does not anticipate", "believes" or variations of these words, expressions or statements, that certain actions, events or results "may", "could", "would", "might" or "will be" taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These and other risk factors are outlined in our annual information form dated July 25, 2025, which is available on SEDAR+ at www.sedarplus.ca. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company's efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws. For more information:Investor Contact
Craig MacPhail
invest@numinusnetwork.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/289713
Original: Numinus Wellness Provides Update Regarding Listing Status

Numinus Wellness Provides Corporate UpdateMarch 13, 2026 5:00 PM
NewsfileVancouver, British Columbia--(Newsfile Corp. - March 13, 2026) - Numinus Wellness Inc. (TSX: NUMI) (OTC: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is providing a corporate update.Corporate UpdateOver the past year, Numinus has undertaken a strategic transformation to streamline its operations and focus on its core business lines. As part of this process, the Company completed the sale of its U.S. wellness clinics, initiated the wind-down of certain non-operating subsidiaries, and implemented leadership changes, including a transition in the Chief Financial Officer role in early 2025.Following these initiatives, Numinus is now focused on two primary operating segments: its clinical trial site network and practitioner training platform.The Company's clinical trial sites continue to support psychedelic drug development programs and have participated in more than twenty clinical studies to date. Cedar Clinical Research remains active in supporting industry-sponsored trials evaluating next-generation mental health treatments.Numinus Training also continues to expand its global practitioner education programs. To date, more than 2,500 practitioners have participated in the Company's training programs, including over 800 research therapists trained to support psychedelic clinical trials. In 2025, the Company expanded its training programs to support drug development sponsors, further strengthening its role within the emerging psychedelic drug development ecosystem.These businesses have continued to operate and grow through the Company's transformation and, together with the Company's clinical operations intellectual property and experience in psychedelic-assisted care delivery, positions the Company for future opportunities within the evolving mental health sector.Audit, Regulatory Update and TSX Delisting ReviewFollowing the recently announced change of auditors, the Company is working diligently to complete the audit of its financial statements for the year ended August 31, 2025 (the "2025 Audit"), to permit the filing of those financial statements, together with related filings, as soon as practicable. The 2025 Audit remains in progress. Completion of the 2025 Audit should enable the Company to complete and file the reports and other disclosures required for Numinus to be current with its continuous disclosure obligations and then apply for the revocation of the current cease trade order (the "CTO") issued by the British Columbia Securities Commission ("BCSC").The Company has been advised that the Toronto Stock Exchange initiated a delisting review of the Company, which commenced in November 2025. The TSX requirements against which Numinus is being reviewed are those relating to financial condition and operating results, the discontinuance or divestiture of a substantial portion of operations, disclosure requirements and change of business.With respect to both the CTO and the delisting review by the TSX, the Company is prioritizing the completion of the 2025 Audit as a necessary step for achieving progress on both matters. When those audited financial statements are filed, or ready to be filed, with their related reports, the Company will then be in a position to reinitiate its work with the BCSC, other securities commissions, other securities regulators towards having the CTO lifted, and responding to the delisting review by the TSX and otherwise pursuing arrangements that will permit Canadian trading of the Company's shares to resume.The Company will provide further updates on these matters as material developments occur.2026 AGMThe Company acknowledges that it did not hold its annual general meeting of shareholders in respect of the year ended August 31, 2025, by the applicable deadline of February 28, 2026, that applies under TSX rules. While that meeting has not yet been scheduled, Numinus intends to schedule the meeting and announce its date once the 2025 Audit is complete and substantial progress has been made towards the revocation of the CTO.OutlookThe Company's transformation over the past year has positioned Numinus to focus on its core capabilities in clinical research and practitioner education within the emerging field of psychedelic-assisted therapies.Numinus is currently evaluating a range of strategic initiatives aimed at strengthening its balance sheet and supporting future growth. These initiatives may include pursuing financing opportunities, strategic partnerships, new business initiatives, and potential mergers or acquisitions.The Company expects to provide additional updates regarding its strategic direction following completion of the audit and the revocation of the CTO.Numinus remains committed to supporting the development of innovative mental health treatments through its clinical research infrastructure, practitioner training programs, and extensive operational experience in psychedelic-assisted care delivery, while positioning the Company to create long-term value for shareholders.About NuminusNuminus Wellness Inc. (TSX: NUMI) (OTC: NUMIF) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic research and training – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society. Learn more at www.numinusnetwork.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.SOURCE Numinus Wellness Inc.Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including, without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are "forward-looking statements". Forward-looking statements can be identified by the use of words such as "expects", "does not expect", "is expected", "believes", "intends", "anticipates", "does not anticipate", "believes" or variations of these words, expressions or statements, that certain actions, events or results "may", "could", "would", "might" or "will be" taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These and other risk factors are outlined in our annual information form dated July 25, 2025, which is available on SEDAR+ at www.sedarplus.ca. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company's efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws. For more information:
Investor Contact
Craig MacPhail
invest@numinusnetwork.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/288422
Original: Numinus Wellness Provides Corporate Update

Numinus Wellness Advises of a Change of AuditorMarch 3, 2026 5:00 PM
NewsfileVancouver, British Columbia--(Newsfile Corp. - March 3, 2026) - Numinus Wellness Inc.  (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is advising of a change of its auditor. The Company's previous auditor, Horizon Assurance LLP ("Horizon") no longer serves as the Company's auditor, with PKF Antares Professional Corporation ("PKF") having confirming its appointment as auditor. On or about January 11, 2026, Numinus was verbally advised by one of the partners of Horizon that Horizon would be resigning as auditor. A written resignation was never provided by Horizon to Numinus. Between that date and early February 2026, management of Numinus continued its efforts in working with Horizon to help advance the audit. However, as management of Numinus determined that Horizon's work on the audit of the August 31, 2025, financial statements appeared to have ceased, Numinus pursued arrangements to engage another auditor for the Company.With PKF having advised that it would agree to be appointed auditor of Numinus effective February 17, 2026, Numinus then provided Horizon and PKF with the notice required under Section 4.11(7) of National Instrument 51-102 (the "Change of Auditor Notice"), setting out its position that effective February 17, 2026, Horizon had resigned of its own initiative and PKF was appointment as auditor. Numinus acknowledges the unresolved issues, and the facts and circumstances leading up to Horizon's resignation but disagrees with Horizon's characterization of the disagreements and unresolved issues. Numinus was acting in good faith to cooperate with Horizon until the time of Horizon's resignation. The Company accepts that Horizon was unable to form an opinion on the Company's financial statements as no audit was completed and no financial statement comments were provided during the engagement. Numinus confirms that the change of independent auditor for the Company has been considered and approved by its Audit Committee and its Board of Directors.Numinus also confirms that at the time of Horizon's resignation, Horizon had not completed the audit of the Company's financial statements for which it had been engaged and had not issued any opinions of the Company's financial statements.About NuminusNuminus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model - including psychedelic research and training - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society. Learn more at www.numinusnetwork.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.SOURCE Numinus Wellness Inc.Forward-looking statements This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including, without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are "forward-looking statements". Forward-looking statements can be identified by the use of words such as "expects", "does not expect", "is expected", "believes", "intends", "anticipates", "does not anticipate", "believes" or variations of these words, expressions or statements, that certain actions, events or results "may", "could", "would", "might" or "will be" taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These and other risk factors are outlined in our annual information form dated July 25, 2025, which is available on SEDAR+ at www.sedarplus.ca. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company's efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws. For more information:
Investor Contact
Craig MacPhail
invest@numinusnetwork.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/286166
Original: Numinus Wellness Advises of a Change of Auditor

This psychedelic sector is taking a Beating!! The whole thing just keeps getting pummeled 👊

The time WILL come, it's just that everyone thought is would happen a bit faster.

Done listening

Good grief

Things are about to get interesting for NUMIF. Lots of action taking place behind the scenes. :)

Just the beginning here folks! The next 2 weeks are going to be WILD!$$$$

Looking good. My top holding in order of size ATAI, MNMD, NUMI. :)

Look at that ask. Hope this is the true reversal and heading back to dollar land

$NUMIF
https://x.com/hannahadad8890/status/1743246190324441340?s=61

LSD for anxiety and psychedelic clinical trials with MindMed CMO, Dr. Daniel Karlin

https://www.youtube.com/watch?v=cdhS8SUCUVU

It was I who mentioned in your telegram to check out numif ;) I see you did! Excellent long term hold in a TFSA account

$NUMIF
https://twitter.com/quabbinr/status/1665415610342293505?s=61

$5-7 probably take a couple years

What's the potential for the pps?

LKYSF: effective Nov. 22,2021 LKYSF will change to NUMIF:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Started a position.

Poised for gainz on Monday Pray they had a productive weekend in the mushroom patch!

I love Numinus. My largest position.

My average is around .77-.78.

Get in now or regret it. This puppy will run. Now is the time. The price is right.

My price target is .99 at least but probably much higher.

$LKYSF -In "#Shroom Boom Article" on Cannabishempwire.com https://cannabishempwire.com/latest-news/f/shrooms-are-about-to-boom-mmefd-shrmf-lrsv-ehvvf-lkysf

A I belive adding long will see averages a going well into dollar terroristic early let get words out other investors.

$NUMI Closes 40 million dollar financing... The financing was increased from the announced 35 million:

https://ceo.ca/@newswire/numinus-announces-closing-of-40-million-bought-deal

$CLSH $TRIP #PSILOCYBIN #MMJ #BITCOIN #ETHEREUM #MONEY #INVESTING #PROFIT #CSE #OTCMARKETS #TSXV

They seem to be good at raising capital

LKYSF $$$$ SOON $$$$ AIMHO

LKYSF $$$$

Good morning LKYSF $$$$

#NUMI 15 minutes later, financing increased from 30 to 35 million:


https://ceo.ca/@nasdaq/numinus-wellness-inc-announces-upsized-bought-deal


#CLSH #TRIP #PSILOCYBIN #MMJ #OTC #CSE #TSXV #INVESTING #PROFIT #MONEY #BITCOIN #ETHEREUM

Hellooooo LKYSF $$$$

#NUMI announces 30 Million Dollar financing:


https://stockhouse.com/news/press-releases/2021/03/15/numinus-wellness-inc-announces-30-million-bought-deal-public-offering


#CLSH #TRIP #BITCOIN #ETHER #PSILOCYBIN #MMJ #OTC #CSE #TSXV #SMALLCAPS #MICROCAPS #MONEY #PROFIT #INVESTING

#NUMI Publicity:


https://ca.proactiveinvestors.com//companies/news/943397/numinus-wellness-is-emerging-as-a-clear-leader-in-the-booming-psychedelics-sector-943397.html?SNAPI


#CLSH #TRIP #BITCOIN #ETHER #MONEY #INVESTING #PROFIT #OTC #CSE #TSXV #MMJ #PSILOCYBIN

How did y’all hear about this in October?


Also: Who’s leg do I have to hump to get a DM when you smart monies find the next one like this?

$NUMI has been doing well over the past 2 days, up approximately 15% since Monday's open. Investors are enjoying today's news release or the following is healthy enough to follow the S&P's move up.

https://stockhouse.com/news/press-releases/2021/03/09/numinus-to-expand-state-of-the-art-psychedelics-research-laboratory

#PSILOCYBIN #MMJ #CLSH #TRIP #MONEY #PROFIT #VENTURE

#NUMI Regulatory approvals place Numinus lab at the forefront of global psychedelics research:

https://lnkd.in/ezSwuyp

#CLSH #TRIP #PSILOCYBIN #MMJ #MONEY #PROFIT #INVESTING #CSE #OTC #TSXV

NEWS from today. Legislation to Decriminalize Possession and Personal Use of Psychedelics in CA.

https://sd11.senate.ca.gov/news/20210218-senator-wiener-introduces-legislation-decriminalize-possession-and-personal-use

Hell yes. Accumulate and hold. I honestly never hold for very long but feels different here. GLTA!

LKYSF news of trial with MAPS!

Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation


Trial enters pre-implementation stage having met several key milestones towards expanding access to patients with PTSD

VANCOUVER, BC, Feb. 18, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to share that the single-arm, open-label, compassionate access1 trial for MDMA-assisted therapy has made significant progress towards treating patients with posttraumatic stress disorder (PTSD). This trial is being pursued in collaboration with MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), the leading developer of the treatment protocols, research, and MDMA-assisted therapy training programs.

"We are excited to share an update on the progress of our MDMA compassionate access trial with the full recognition that existing therapies for PTSD are inadequate," said Payton Nyquvest, CEO of Numinus. "At Numinus, we are pleased to help foster a promising regulatory landscape that will contribute to a better understanding that psychedelic-assisted psychotherapies are a viable, safe, and necessary avenue for expanding existing treatment options. We look forward to continued collaboration with the Multidisciplinary Association of Psychedelics for Studies (MAPS PBC) and will work together to provide those experiencing PTSD with more treatment options."

This first-of-its-kind trial in Canada has advanced and successfully transitioned into the pre-implementation stage at Numinus' Vancouver clinic. This follows the successful completion of several milestones, starting with the recruitment of therapists, physicians, and staff in preparation for participant enrolment and the ultimate analysis of therapy outcomes. The highly qualified cohort of medical staff will be responsible for collecting safety data for Health Canada to further implement key research that supports individuals living with PTSD who have not benefited from existing treatment options.

In November 2020, eight Numinus therapists graduated from Part B of the MAPS MDMA therapist training program. Through their roles within the trial, they will complete the supervision requirement for certification as fully qualified MDMA therapists.

A draft MDMA-assisted therapy protocol for PTSD has been adapted for the trial, including clear guidance surrounding necessary screening processes, patient health histories, and indications and potential contraindications before accepting participants. Initial regulatory meetings with Health Canada to define the trial's implementation science strategy have been completed, and the next steps will include obtaining ethical and Health Canada approvals to allow the recruitment of participants according to COVID-19 public health protocols.

"Developing a skilled workforce is a key challenge for the safe delivery of psychedelic-assisted therapies, so we are pleased to engage with Numinus to train therapists in the MDMA-assisted therapy protocol for PTSD," said Amy Emerson, CEO of MAPS PBC.

Numinus is also pleased to announce that its Medical and Therapeutic Services Director, Dr. Devon Christie, will serve as both the trial's Principal Investigator and as a therapist. Dr. Christie is a family physician with a focus in multidisciplinary pain management, is a certified Relational Somatic Therapist, and is already MAPS-trained in the delivery of the MAPS MDMA-assisted therapy for PTSD.

"I am thrilled to be involved in a long-awaited clinical program that will help pave the way towards wider use of MDMA-assisted psychotherapy for those experiencing PTSD," said Dr. Christie. "The key milestones announced today are a true testament to our teams' commitment to establishing the physical, technical, clinical, and human resource infrastructure needed to swiftly move through the trial's formal implementation stages and ultimately towards the recruitment of the first participant."

https://www.newswire.ca/news-releases/numinus-announces-milestones-in-compassionate-access-trial-for-mdma-assisted-therapy-in-collaboration-with-maps-public-benefit-corporation-819950387.html

See post this replied to

Nice start to the morning

THIS TICKER IS NOW PINK CURRENT ;)

Welcome magic mushroom friends!

ADMINS - PLEASE REMOVE GREY MARKET NOTIFICATION UP TOP. This ticker is Pink Current. Much appreciated, thank you.

https://www.otcmarkets.com/stock/LKYSF/overview

This thing hasn’t even gotten started yet. It’s 1/10 of the market cap of MMEDF... and psychedelic psychotherapy is going to be HUGE. So much room to go imo

anyone else nervous about that baby gap on the chart?

New article quoting CEO of LKYSF....

Psychedelics Sentiment Strong, Investors Ready for New Year

After a welcome party of a year for the psychedelics investing space, how exactly does investor appetite stand as the new year begins?

The psychedelics investment proposal has started to grab the attention of investors across the board as more companies begin hitting the public markets.

While it’s clear attention is rising, the Investing News Network (INN) spoke with two companies to get their thoughts on investor interest and how they see this new market.

“It seems incredibly strong,” Ronan Levy, co-founder and executive director with Field Trip Health (CSE:FTRP), said of current investor sentiment towards psychedelics.

Levy said his company recently completed a bought deal raising, which was oversubscribed by about two and a half times from the original deal. “The demand seems to be pretty palpable, both on an institutional level as well as on a retail level,” he told INN.

The new year has brought an uptick in offerings from psychedelics companies. In January, companies such as Mind Cure Health (CSE:MCUR,OTCQB:MCURF), Havn Life Sciences (CSE:HAVN), Cybin (NEO:CYBN) and Mind Medicine (MindMed) (NEO:MMED,OTCQB:MMEDF) all confirmed significant investment deals.

Payton Nyquvest, chairman and CEO of Numinus Wellness (TSXV:NUMI), told INN the psychedelics industry has experienced a perfect storm of validation from the financial community as well as the regulatory space thanks to increased acceptance from investors, along with recent policy updates that have further opened the doors to psychedelics.

Nyquvest said he spends the majority of his time with potential investors clarifying key questions about the space, such as the actual logistics of psychedelics-assisted psychotherapy, regulatory timelines for policy changes and the legal framework in place.

When it comes to the type of investors associated with the space at the moment, Levy said there certainly are some looking for an exciting trade opportunity given the bump in attention for this market.

However, many are appreciating the long-term nature of the psychedelics industry.

“Most of the investors I can say that we brought in as part of our our bought deal understood the long-term potential and that this is an evolving industry and it’s going to have its ups and downs,” Levy said.

psychedelics outlook

How to differentiate psychedelics investments?
With increased demand from the market, the psychedelics space has seen a rush of brand new listings and emerging companies fighting for the attention of a growing investor base.

Nyquvest told INN he recommends that investors pay attention to the people involved with these companies first and foremost. “My question is always, ‘What is their research and implementation plan?’ And then looking at what it costs,” the Numinus executive said.

He stressed that investors need to be ready to comprehend the demands of research work and the amount of time this represents for companies.

Nyquvest said he’s encouraged by the discussions on due diligence that he’s seeing surrounding the space as more companies go public.

First psychedelics fund shows growing investor demand
At the end of January, Horizons ETFs Management (Canada) launched the first exclusively dedicated psychedelics exchange-traded fund (ETF) in the industry. The Horizons Psychedelic Stock Index ETF (NEO:PSYK) came to the market with a basket of 17 stocks.

Steve Hawkins, CEO of Horizons ETFs, told INN his company started doing research on psychedelics early in 2020, when attention was first starting to fall on the sector.

The firm was previously responsible for launching the first Canadian cannabis ETF, and the executive said for that reason Horizons ETFs quickly started getting questions and seeing general interest from investors about a potential psychedelics ETF.

Don’t forget to follow us @INN_Cannabis for real-time updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.





https://investingnews.com/daily/life-science-investing/psychedelics-investing/psychedelics-sentiment-strong-new-year/

Numinus Wellness Completes Acquisition of Montreal-based Mindspace Wellbeing

Acquisition expands Numinus' presence while improving psychedelic-assisted therapy landscape in Canada

VANCOUVER, BC, Feb. 8, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), has closed its acquisition of Mindspace Psychology Services Inc. (DBA Mindspace Wellbeing), a leader and pioneer in psychedelic programming. The purchase agreement was previously announced on December 15, 2020.

Founded by Dr. Joe Flanders in 2011, Mindspace will continue under Dr. Flanders' leadership. The acquisition expands Numinus' presence into Quebec, building on its Vancouver office with two established locations and extensive virtual services as well as insights garnered from a decade of successful clinic management.

Terms of the agreement:
Numinus paid the following consideration to complete the Transaction:

$500,000 in cash upon closing of the Transaction
A time-based payout of 441,176 common shares of Numinus issued over the course of 24 months
$100,000 in Numinus shares, issued at Market Price, per year on each of the first three (3) anniversaries of the Closing Date
A multi-year performance payout of $800,000 in Numinus shares, issued at Market Price



https://www.newswire.ca/news-releases/numinus-wellness-completes-acquisition-of-montreal-based-mindspace-wellbeing-891369191.html

Numinus singled out in article.



insert-text-here

NUMI, setting up run just like late Nov, Daily chart almost the same as $2 run in Nov

Doc featuring psychedelics coming...

Veracity: The Psychedelic Frontier

A war veteran’s battle with PTSD takes him on a journey into the world of psychedelics. Watch Veracity: The Psychedelic Frontier, featuring Russell Peters, on Jan. 25 at 10 p.m.


https://toronto.citynews.ca/video/2021/01/12/veracity-the-psychedelic-frontier/

Psychedelic conference next week should bring more eyes and $ to psychedelics!

https://www.prnewswire.com/news-releases/kcsa-strategic-communications-announces-agenda-for-the-kcsa-psychedelics-investor-conference-on-january-26-27-2021-301212704.html

This should be good for the trading of LKYSF common to have warrants listed and freely trading....

VANCOUVER, BC, Jan. 21, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted for listing the 12,683,925 warrants (the "Warrants") issued pursuant to the Company's previously announced prospectus offering that closed on December 29, 2020.

The Warrants will be listed for trading on the TSXV under the symbol "NUMI.WS" effective at market open on Monday, January 25, 2021.

Each Warrant entitles the holder thereof to acquire one common share of the Company at an exercise price of $0.90 until December 29, 2022. The Warrants were issued pursuant to, and are governed by, the terms of a warrant indenture dated December 29, 2020 (the "Warrant Indenture") between the Company and Computershare Trust Company of Canada. A copy of the Warrant Indenture is available under the Company's SEDAR profile at www.sedar.com.




https://www.newswire.ca/news-releases/numinus-announces-listing-of-warrants-893519003.html